SCHEMBL9510156

SCHEMBL9510156

CCCCOc1ccc(C#Cc2ccc(CCC)c(F)c2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 3/20 0.39
CYP2D6 P10635 5/20 0.39
CYP3A4 P08684 3/20 0.39
MCHR1 Q99705 1/20 0.38
CYP1A2 P05177 4/20 0.38
CYP19A1 P11511 4/20 0.38
CYP2C9 P11712 4/20 0.38
CYP2C19 P33261 4/20 0.38
LTA4H P09960 3/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA7 P36544 1/20 0.37
CHRNA4 P43681 1/20 0.37
NR5A1 Q13285 1/20 0.36
CYSLTR2 Q9NS75 1/20 0.36
CYSLTR1 Q9Y271 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9510227 0.97 NR5A1 (0.41) ACACBCYP2D6CYP3A4MCHR1LTA4H
SCHEMBL9512429 0.94 ACACB (0.43) ACACBMCHR1CHRNB2CHRNB4CHRNA3
SCHEMBL9512289 0.94 ACACB (0.39) ACACBCYP2D6CYP3A4MCHR1CYP1A2
SCHEMBL9512426 0.93 CNR2 (0.40) ACACBCYP2D6CYP3A4MCHR1CYP1A2
SCHEMBL9512387 0.92 ACACB (0.41) ACACBCYP2D6CYP3A4MCHR1
SCHEMBL9512534 0.92 CNR2 (0.42) LTA4HNR5A1CYSLTR2CYSLTR1KDM4E
SCHEMBL10509743 0.92 CYSLTR2 (0.37) ACACBCYSLTR2CYSLTR1
SCHEMBL9511360 0.91 ACACB (0.41) ACACBNR5A1CYSLTR2CYSLTR1
SCHEMBL9508844 0.90 ACACB (0.40) ACACB
SCHEMBL9512263 0.90 ACACB (0.42) ACACBCYP2D6CYP3A4MCHR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0308438-B1 LIQUID CRYSTAL PHASE CONTAINING TOLANES MERCK PATENT GmbH (DE) 1993-09-29 EP disclosed